Intra Cellular Therapies Stock Net Income
ITCIDelisted Stock | USD 131.87 0.03 0.02% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Intra Cellular's long-term financial health and intrinsic value.
Intra |
Intra Cellular Therapies Company Net Income Analysis
Intra Cellular's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Intra Cellular Net Income | (74.68 M) |
Most of Intra Cellular's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra Cellular Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Intra Cellular Therapies reported net income of (74.68 Million). This is 121.88% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 113.08% higher than that of the company.
Intra Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra Cellular's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra Cellular could also be used in its relative valuation, which is a method of valuing Intra Cellular by comparing valuation metrics of similar companies.Intra Cellular is currently under evaluation in net income category among its peers.
Intra Fundamentals
Return On Equity | -0.0858 | |||
Return On Asset | -0.0696 | |||
Profit Margin | (0.11) % | |||
Operating Margin | (0.15) % | |||
Current Valuation | 13.06 B | |||
Shares Outstanding | 106.52 M | |||
Shares Owned By Insiders | 2.48 % | |||
Shares Owned By Institutions | 96.40 % | |||
Number Of Shares Shorted | 2.67 M | |||
Price To Earning | (6.56) X | |||
Price To Book | 12.23 X | |||
Price To Sales | 20.63 X | |||
Revenue | 680.85 M | |||
Gross Profit | 387.77 M | |||
EBITDA | (116.72 M) | |||
Net Income | (74.68 M) | |||
Cash And Equivalents | 628.74 M | |||
Cash Per Share | 6.64 X | |||
Total Debt | 16.98 M | |||
Debt To Equity | 0.04 % | |||
Current Ratio | 9.81 X | |||
Book Value Per Share | 10.81 X | |||
Cash Flow From Operations | (73.18 M) | |||
Short Ratio | 1.20 X | |||
Earnings Per Share | (0.73) X | |||
Target Price | 132.0 | |||
Number Of Employees | 860 | |||
Beta | 0.46 | |||
Market Capitalization | 14.05 B | |||
Total Asset | 1.37 B | |||
Retained Earnings | (1.69 B) | |||
Working Capital | 1.1 B | |||
Current Asset | 541.82 M | |||
Current Liabilities | 140.69 M | |||
Net Asset | 1.37 B |
About Intra Cellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intra Cellular Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra Cellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra Cellular Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in commodities. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |